Intensity Therapeutics jumps on FDA's 'orphan drug' tag for cancer treatment

Intensity Therapeutics

07/09/2023 15:12

** Shares of Intensity Therapeutics  INTS.O  rise 4.7% to
$5.63
    ** Co says its treatment for soft tissue sarcoma (STS)
received "orphan drug" designation from the U.S. FDA
    ** Soft tissue sarcoma is a broad term for cancers that
start in soft tissues (muscle, tendons, fat, lymph and blood
vessels, and nerves) - NIH
    ** "Orphan drug" status is given to drugs that treat rare
conditions and are protected through a series of government
incentives once in the market
    ** Up to last close, shares down 9.7% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))